Earnings Per Share

12 Months Ended

Oct. 02, 2020

EARNINGS PER SHARE

The following table set forth the computation for basic and diluted net income (loss) per share of common stock (in thousands, except per share data):


	Fiscal Years
	2020		2019		2018
Numerator:
Loss from continuing operations	$	(46,078)	$	(383,798)	$	(133,762)
Loss from discontinued operations	—		—		(6,215)
Net loss	(46,078)		(383,798)		(139,977)
Warrant liability gain	—		—		(27,646)
Net loss attributable to common stockholders	$	(46,078)	$	(383,798)	$	(167,623)

Denominator:
Weighted average common shares outstanding-basic	66,606		65,686		64,741
Dilutive effect of warrants	—		—		570
Weighted average common shares outstanding-diluted	66,606		65,686		65,311
Common stock earnings per share-basic:
Continuing operations	$	(0.69)	$	(5.84)	$	(2.07)
Discontinued operations	—		—		(0.10)
Net common stock earnings per share-basic	$	(0.69)	$	(5.84)	$	(2.16)
Common stock earnings per share-diluted:
Continuing operations	$	(0.69)	$	(5.84)	$	(2.47)
Discontinued operations	—		—		(0.10)
Net common stock earnings per share-diluted	$	(0.69)	$	(5.84)	$	(2.57)

As of October 2, 2020, we had warrants outstanding which were reported as a liability on the consolidated balance sheet. During fiscal years 2019 and 2018, we recorded gains of $0.8 million and $27.6 million, associated with adjusting the fair value of the

warrants, in the Consolidated Statements of Operations primarily as a result of declines in our stock price. When calculating earnings per share we are required to adjust for the dilutive effect of outstanding common stock equivalents, including adjustment to the numerator for the dilutive effect of contracts that must be settled in common stock. During fiscal years 2020 and 2019, we excluded the effects of the warrant and the respective 639,133 and 214,303 potential shares of common stock issuable upon exercise of warrants as the inclusion would be anti-dilutive. During the fiscal year ended September 28, 2018, we adjusted the numerator to exclude the warrant gain $27.6 million, and we also adjusted the denominator for the dilutive effect of the incremental warrant shares of 569,667 under the treasury stock method. For fiscal year 2018, the table above excludes the effects of 375,940 shares of potential shares of common stock issuable upon exercise of stock options, restricted stock and restricted stock units as the inclusion would be anti-dilutive. The table excludes the effects of 1,755,973 and 386,552 shares for fiscal years 2020 and 2019, respectively, of potential shares of common stock issuable upon exercise of stock options, restricted stock, restricted stock units and warrants as the inclusion would be anti-dilutive.